

Practitioner's Docket No. MPI98-052P1RDV10DV1M

USSN: 10/786,501

In the Claims:

Please amend claims 49 and 55. This listing of the claims replaces all prior versions and listings of claims in the applications:

1-26 (Canceled)

27-48 (Canceled)

49. (Currently Amended): An isolated antibody, or portion thereof, that specifically binds to a polypeptide selected from the group consisting of:

a) a polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:8, wherein said polypeptide has kinase activity; and

b) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:7 or 9, wherein said polypeptide has kinase activity; and

~~c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleic acid comprising the nucleotide sequence contained in the plasmid deposited with the ATCC as Accession number 203309.~~

50. (Previously Presented): The antibody, or portion thereof, of claim 49, wherein said antibody is selected from the group consisting of:

- i) a monoclonal antibody;
- ii) a polyclonal antibody;
- iii) a humanized antibody;
- iv) a chimeric antibody; and
- v) a murine antibody.

51. (Previously Presented): The antibody, or portion thereof, of claim 49, wherein said portion is a F(ab) fragment or a F(ab')₂ fragment.

52. (Previously Presented): The antibody, or portion thereof, of claim 49, wherein said antibody binds to amino acid residues 5-164 of SEQ ID NO:8.

(Page 4 of 11)

Practitioner's Docket No. MPI98-052P1RDV10DV1M

USSN: 10/786,501

53. (Previously Presented): The antibody, or portion thereof, of claim 49, wherein said antibody is detectably labeled.

54. (Previously Presented): The antibody, or portion thereof, of claim 53, wherein the detectable label is selected from the group consisting of:

- a) enzymes;
- b) prosthetic groups;
- c) fluorescent materials;
- d) luminescent materials;
- e) bioluminescent materials; and
- f) radioactive materials.

55. (Currently Amended): An isolated antibody, or portion thereof, that specifically binds to a polypeptide selected from the group consisting of:

- a) the polypeptide comprising the amino acid sequence of SEQ ID NO:8; and
- b) the polypeptide encoded by the nucleic acid molecule of SEQ ID NO:7 or 9; and
- ~~c) the polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with the ATCC as Accession number 203309.~~

56. (Previously Presented): The antibody, or portion thereof, of claim 55, wherein said antibody is selected from the group consisting of:

- i) a monoclonal antibody;
- ii) a polyclonal antibody;
- iii) a humanized antibody;
- iv) a chimeric antibody; and
- v) a murine antibody.

57. (Previously Presented): The antibody, or portion thereof, of claim 55, wherein said portion is a F(ab) fragment or a F(ab')₂ fragment.

(Page 5 of 11)

Practitioner's Docket No. MPI98-052P1RDV10DV1M

USSN: 10/786,501

58. (Previously Presented): The antibody, or portion thereof, of claim 55, wherein said antibody binds to amino acid residues 5-164 of SEQ ID NO:8.

59. (Previously Presented): The antibody, or portion thereof, of claim 55, wherein said antibody is detectably labeled.

60. (Previously Presented): The antibody, or portion thereof, of claim 59, wherein the detectable label is selected from the group consisting of:

- a) enzymes;
- b) prosthetic groups;
- c) fluorescent materials;
- d) luminescent materials;
- e) bioluminescent materials; and
- f) radioactive materials.

61. (Withdrawn): A method for detecting the presence of a polypeptide selected from the group consisting of:

i) a polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:8, wherein said polypeptide has kinase activity;

ii) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:7 or 9, wherein said polypeptide has kinase activity; and

iii) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleic acid comprising the nucleotide sequence contained in the plasmid deposited with the ATCC as Accession number 203309;

in a sample comprising:

- a) contacting the sample with an antibody of claim 49 which selectively binds to the polypeptide; and
- b) determining whether the antibody binds to the polypeptide in the sample to thereby detect the presence of the polypeptide in the sample.

62. (Withdrawn): A method for detecting the presence of a polypeptide selected from the group consisting of:

(Page 6 of 11)

Practitioner's Docket No. MPI98-052P1RDV10DV1M**USSN: 10/786,501**

- a) the polypeptide comprising the amino acid sequence of SEQ ID NO:8;
- b) the polypeptide encoded by the nucleic acid molecule of SEQ ID NO:7 or 9; and
- c) the polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with the ATCC as Accession number 203309

in a sample comprising:

- i) contacting the sample with an antibody of claim 55 which selectively binds to the polypeptide; and
- ii) determining whether the antibody binds to the polypeptide in the sample to thereby detect the presence of the polypeptide in the sample.

63. (Previously Presented): A kit comprising the antibody of claim 49 and instructions for use.

64. (Previously Presented): A kit comprising the antibody of claim 55 and instructions for use.

(Page 7 of 11)